ArticleBMC medicine2025
Evaluating the effectiveness of international travel controls to identify MPXV-infected travelers: a simulation study.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundIn August 2024, the World Health Organization (WHO) declared a public health emergency due to the rapid spread of mpox in Africa and beyond. International travel controls (ITCs), such as health screening and viral testing, could help avoid/delay the global spread of MPXV, fostering preparedness and response efforts. However, it is not clear whether the viral tests at immigration are sufficient to avoid introduction of MPXV and which samples should be used on the viral tests.
methodsWe conducted a simulation study using epidemiological and viral load data to assess the effectiveness of health screening and polymerase chain reaction (PCR) testing at immigration. The primary outcome was the proportion of MPXV-infected travelers identified under various international travel control policies. To estimate time-varying false-negative rates of PCR tests with different detection limits, we employed viral dynamics models calibrated to data from three anatomical sites: oropharynx, saliva, and rectum. Additionally, we simulated the effects of these control measures on the recommended duration of a post-entry monitoring period. Travelers were assumed to depart from mpox-affected countries, defined as those with ongoing MPXV transmission, potentially representing both historically endemic regions and countries with recent outbreaks.
resultsOur results show that under an endemic scenario, the combination of health screening and PCR testing using saliva swabs identifies approximately 74% of MPXV-infected travelers. Using rectal swabs slightly improves detection, identifying up to 79% of infected individuals. A comparable improvement can also be achieved by increasing test sensitivity (i.e., reducing the detection limit from 250 to 10 copies/mL). Based on the distribution of post-entry incubation periods, we estimated that travelers from mpox-affected regions should self-monitor and adopt precautionary behavior for at least 16 days to mitigate the risk of onward transmission.
conclusionsHealth screening and PCR testing at immigration are likely to miss a significant proportion of MPXV-infected travelers, thus a lengthy quarantine period would be required to prevent onward local transmission. Careful consideration on other factors such as economic costs and likelihood of widespread local outbreak will need to be weighed against the adoption of these measures to prevent local mpox transmission given MPXV transmissibility and severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.